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Introduction
Despite advances in HIV commercial therapies, includ-
ing fixed-dose combinations, unprecedented proportions
of HIV patients remain without therapeutic options due
to lack of access to treatment and epidemiologically sig-
nificant proportions of multi-class drug resistance that
are driving morbidity levels in both developed and
resource-poor settings. The need to emphasize the
development of therapeutic options with the potential to
abrogate these correlating trends are receiving insuffi-
cient dedication of resources, as new clinical strategies
do not address these enduring disparities. GenePro, a
therapeutic vaccine candidate, has shown preclinical effi-
cacy via publicly sponsored research that demonstrates
the potential to address a current therapeutic issue.
Materials and methods
The GenePro therapeutic construct includes strong lenti-
viral promoter and 7 out of 9 HIV genes: Gag, pol, tat, rev,
vpu, env and nef. In a preclinical study, kinetic analyses on
splenocytes of BALB/c mice that were immunized by
a single injection with a GenePro were performed.
IFN-gamma-ELISPOT and multiparametric FACS analysis
were conducted to characterize the induced CMI
response. Animals immunized with a single high dose of
GenePro were monitored longitudinally for vaccine-
induced IR using multiparametric flow cytometry-based
assays.
Results
Comprehensive analysis demonstrated the capacity of a
single high dose of HIV DNA vaccine alone to induce
long-lasting and polyfunctional T-cell responses in the
nonhuman primate model. In preclinical studies, GenePro
has been found to generate the HIV-specific memory cells
found in elite controllers and reconstitution of the
immune system. The TriGrid delivery system increases
DNA delivery efficiency by up to 1,000 fold. This approach
has less toxicity and no drug resistance and may allow for
STIs from ART.
Conclusion
Data from initial investigations of GenePro indicate
improvements in immune response and generation of
HIV-specific memory cells that induced immune responses
by altered HIV DNA constructs, which synthetically mimic
virologic responses of elite controllers. Advancement of
GenePro into human studies will serve as a hallmark in
continuing commercial efforts to discover a universal
address for the global AIDS crisis.
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